Our Opinion

Rain Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“The activity observed by Tarlox in NRG1 fusion models is very exciting,” said Avanish Vellanki, chief executive officer of Rain Therapeutics. “The potency of tarlox observed across various in vitro and patient-derived animal studies was intuitive as NRG1 tumors rely on HER-signaling.” Read the following article

Company Description

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Company Website: https://www.rainthera.com